USE OF A COMPUTERIZED CLINICAL DECISION SUPPORT (CCDS) TOOL IN PRIMARY CARE INCREASES RATES OF CONFIRMATORY TESTING IN PATIENTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AT RISK FOR ADVANCED LIVER FIBROSIS: A PILOT STUDY

被引：0
|
作者：
Miller, James [1 ]
Xiao, Ted [1 ]
Witek, Lauren [1 ]
Bundy, Richa [1 ]
Moses, Adam [1 ]
Obermiller, Corey [1 ]
Dharod, Ajay [1 ]
Russo, Mark [2 ]
Rudnick, Sean [3 ]
机构：
[1] Wake Forest Univ, Sch Med, Winston Salem, NC 27101 USA
[2] Carolinas Med Ctr, Charlotte, NC USA
[3] Atrium Hlth Wake Forest Baptist, Winston Salem, NC USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1185
引用
收藏
页码：S903 / S904
页数：2
相关论文
共 41 条
  • [21] PROGNOSTIC VALUE OF THE AASLD 2-STEP APPROACH IN THE IDENTIFICATION OF ADVANCED LIVER FIBROSIS IN 16,603 PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN THE VCTE-PROGNOSIS STUDY
    Yip, Terry Cheuk-Fung
    Lee, Hye Won
    Lin, Huapeng
    Tsochatzis, Emmanuel
    Petta, Salvatore
    Bugianesi, Elisabetta
    Yoneda, Masato
    Zheng, Ming-Hua
    Hagstrom, Hannes
    Boursier, Jerome
    Luis Calleja, Jose
    Goh, Boon Bee George
    Chan, Wah Kheong
    Gallego-Duran, Rocio
    Sanyal, Arun
    de Ledinghen, Victor
    Newsome, Philip
    Fan, Jiangao
    Castera, Laurent
    Lai, Michelle
    Harrison, Stephen
    Fournier, Celine
    Wong, Grace
    Pennisi, Grazia
    Armandi, Angelo
    Nakajima, Atsushi
    Liu, Wen-Yue
    Shang, Ying
    De Saint Loup, Marc
    Llop, Elba
    Teh, Kevin
    Lara Romero, Carmen
    Asgharpour, Amon
    Mahgoub, Sara
    Chan, Mandy
    Canivet, Clemence
    Romero-Gomez, Manuel
    Kim, Seung Up
    HEPATOLOGY, 2024, 80 : S810 - S812
  • [22] Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial
    Perva, Iulia Teodora
    Simina, Iulia Elena
    Bende, Renata
    Motofelea, Alexandru Catalin
    Emandi, Adela Chirita
    Andreescu, Nicoleta
    Sima, Alexandra
    Vlad, Adrian
    Sporea, Ioan
    Zimbru, Cristian
    Tutac, Paul Calin
    Puiu, Maria
    Niculescu, Mihai Dinu
    MEDICINA-LITHUANIA, 2024, 60 (08):
  • [23] ASSOCIATION BETWEEN USE OF ANTI-HYPERTENSIVE DRUGS AND RISK OF HEPATOCELLULAR CARCINOMA (HCC) IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) PATIENTS WITH CIRRHOSIS
    Elhariri, Ahmed
    Hassan, Manal
    ELsheikh, Mazen
    El Sabagh, Ahmed
    Ibrahim, Mohamad Ali
    Bhongade, Megha
    Albarouki, Sali
    Nayak, Anish
    Karouni, Youseph
    Jalal, Prasun
    HEPATOLOGY, 2024, 80 : S859 - S860
  • [24] Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study
    Lin, Ming
    Gao, Bowen
    Peng, Mengnan
    Chen, Xuefang
    Xiao, Huanming
    Shi, Meijie
    Zhang, Xiujuan
    Zeng, Folai
    Chi, Xiaoling
    FRONTIERS IN PHYSIOLOGY, 2024, 15
  • [25] Diagnostic performance of non-invasive tests in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) with increased alcohol intake (MetALD) in a primary care setting
    Yoon, Eileen
    An, Jihyun
    Il Kim, Ha
    Sohn, Joo Hyun
    Park, Huiyul
    Ahn, Sang Bong
    Oh, Joo Hyun
    Oh, Hyunwoo
    Lee, Hyo Young
    Jun, Dae Won
    JOURNAL OF HEPATOLOGY, 2024, 80 : S148 - S148
  • [26] LIVER AND NON-LIVER OUTCOMES OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) VERSUS MASLD WITH INCREASED ALCOHOL USE (METALD) STRATIFIED BY PRESENCE OF VIRAL HEPATITIS: A STUDY OF 850,156 REAL-WORLD PATIENTS IN THE US
    Nguyen, Vy H.
    Zhang, Xinrong
    Cheung, Ramsey
    Nguyen, Mindie H.
    GASTROENTEROLOGY, 2024, 166 (05) : S1655 - S1655
  • [27] CLINICAL CHARACTERISTICS AND FIB-4 RISK STRATIFICATION OF PRIMARY CARE PATIENTS WITH OBESITY, DIABETES, OR BOTH: REAL-WORLD IMPLICATIONS FOR ADOPTING A FIB-4 REFERRAL ALGORITHM TO DETECT METABOLIC DYSFUNCTION-ASSOCIATION STEATOTIC LIVER DISEASE (MASLD) WITH ADVANCED FIBROSIS
    Chu, Janet
    Khalili, Mandana
    Goldman, Max
    Hameed, Bilal
    Ha, Nghiem
    Fox, Rena
    HEPATOLOGY, 2024, 80 : S868 - S869
  • [28] FIBROSIS RISK STRATIFICATION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE PATIENTS WITH DIABETES IN TAIWAN- A MULTI-CENTER COHORT STUDY
    Huang, Jee-Fu
    Yeh, Ming-Lun
    Lee, Mei-Hsuan
    Dai, Chia-Yen
    Huang, Chung-Feng
    Yu, Ming-Lung
    Chuang, Wan-Long
    HEPATOLOGY, 2024, 80 : S895 - S895
  • [29] EUS-guided shear wave elastography for fibrosis screening in patients with obesity and metabolic dysfunction-associated steatotic liver disease: a pilot study (with video)
    Wang, Thomas J.
    Jirapinyo, Pichamol
    Shah, Raj
    Schuster, Kimberly
    Papke, David J.
    Thompson, Christopher C.
    Doyon, Laura
    Lautz, David B.
    Ryou, Marvin
    GASTROINTESTINAL ENDOSCOPY, 2025, 101 (02)
  • [30] SERUM NONINVASIVE TESTING SCORES AND MODELING TO PREDICT INTERMEDIATE OR HIGH RISK FOR ADVANCED FIBROSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN A TYPE 2 DIABETES (T2D) POPULATION COHORT
    Arndt, Gretchen
    Lindsey, Mark
    Swartwood, Sheila
    Arrigain, Susana
    Moscoso, Rocio Lopez
    Wieland, Amanda
    Jensen, Thomas
    HEPATOLOGY, 2024, 80 : S438 - S439
12345